Alumis Inc. Announces $300M Common Stock Offering to Fund NDA Filing and Operations
ALMS has more than doubled off its 52-week low of $2.76 on elevated volume (4.3× avg).
Summary
Alumis Inc. is raising approximately $300 million through a common stock offering to fund the potential NDA filing and launch preparations for envudeucitinib in plaque psoriasis, as well as general corporate purposes, addressing a previously disclosed "going concern" risk.
Key Events · Financing and Capital Events · ALMS
-
Public Offering Announced
Alumis Inc. is offering 17,650,000 shares of common stock at $17.00 per share, aiming to raise approximately $300 million in gross proceeds.
-
Significant Capital Raise
The offering is expected to generate net proceeds of approximately $281.5 million, which is a substantial amount for the company.
-
Addresses Going Concern
The proceeds are crucial for the company to fund operations into the fourth quarter of 2027, addressing previously disclosed "substantial doubt about its ability to continue as a going concern."
-
Funds Product Advancement
Capital will be used for potential NDA regulatory filing and launch preparations for envudeucitinib in plaque psoriasis, following positive Phase 3 results, and for other pipeline development.
Analysis · ALMS · Life Sciences
This substantial capital raise is critical for Alumis Inc., as the company previously indicated "substantial doubt about its ability to continue as a going concern." The offering, which will generate approximately $281.5 million in net proceeds, is intended to fund the potential NDA regulatory filing and launch preparations for envudeucitinib in plaque psoriasis, following recent positive Phase 3 clinical trial results. It will also support further clinical development and general operations, extending the company's cash runway into the fourth quarter of 2027. While the offering is dilutive, priced at $17.00 per share compared to a recent market price of $17.92, it provides essential funding to advance its lead product candidate towards commercialization and mitigate immediate financial risks.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALMS was trading at $18.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $2.76 to $22.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.